$NUTX

Pertento entities, Eduardo Marques list holdings in Nutex Health (NUTX) on 13G/A

An amendment to a Schedule 13G/A filing reveals that Pertento-related entities and Eduardo Marques have reported significant holdings in Nutex Health (NUTX). Pertento Partners LLP, Pertento Advisors LLC, and Eduardo Marques each hold 405,029 shares, representing 5.9% of the common stock, while Pertento Master Fund Limited owns 361,201 shares, or 5.3%. The filing, dated May 1, 2026, and signed May 7, 2026, indicates a passive investment intent.

Original reporting
Published May 8, 2026, 4:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 8, 2026, 5:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$NUTX
Neutral
medium confidence
Mentioned
$NUTX
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$NUTXNeutralLow
01

Why it matters

This passive investment does not signal an imminent change in company direction but highlights institutional confidence or interest.

02

Market read

The disclosure suggests institutional interest but lacks immediate trading implications; long-term investors may find it noteworthy.

03

What to watch

Lack of recent operational news or financial performance data limits the ability to assess true company health or growth prospects.

Timing: long-term

Background

Pertento-related entities and Eduardo Marques have increased their passive stake in Nutex Health, indicating a long-term interest without immediate strategic moves.

Company-level read

Ticker impact

$NUTXNeutralMedium confidence
Context

Significant passive holdings reported by institutional entities suggest potential market influence.

Expected impact

Limited immediate price movement expected; potential for stabilization around current levels unless further news emerges.

Evidence & confidence

Passive holdings typically do not trigger short-term trading volatility, but they can influence market perception over time.

Market effects

The healthcare sector may see cautious investor sentiment due to increased institutional interest in niche providers.

Limited regional impact; focus remains on U.S.-based healthcare providers.

Minimal global relevance given the company's regional focus and passive investment nature.

Counterpoint

Passive holdings could precede strategic initiatives, such as acquisitions or management changes, which might positively influence stock price in the future.

Key entities

  • Pertento Partners LLP

    A private equity and investment advisory firm.

  • Pertento Advisors LLC

    A firm providing investment management services.

  • Eduardo Marques

    A notable investor with passive holdings in NUTX.

Related articles

$NUTXMed

NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

Nutex Health Inc. (NASDAQ: NUTX) reported Q2 2026 results for the three and six months ended June 30, 2026. Net income attributable rose to $65.8M (diluted EPS $9.38) for Q2, versus a loss in 2025. Six-month net income was $112.6M (EPS $15.87). Revenue fell to $427.2M for six months. Operating cash flow was $109.7M. Hospital visits increased.

$NUTXMed

Nutex Health Inc. (NUTX): Results of Operations and Financial Condition

Nutex Health Inc. (NUTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 nutx-20260630xexx99.htm EX-99.1 Document NUTEX HEALTH REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS HOUSTON, TX − (PRNewswire) – AUGUST 6, 2026 – Nutex Health Inc. (“Nutex Health” or the “Company”) (NASDAQ: NUTX), today announced financial results for the three and six

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).